SAN DIEGO, January 30, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious ...

ARCT opened at $17.12 on Friday. The stock has a market cap of $463.78 million, a PE ratio of -7.71 and a beta of 2.63. The business has a 50 day moving average of $17.28 and a 200-day moving ...

SAN DIEGO, February 04, 2025--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious ...

Designer babies may sound like science fiction, but they’re becoming increasingly possible as gene editing technology to treat and prevent genetic diseases evolves. How scientists should use it ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $63.00. Ed Arce has given his Buy ...

ARCT has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on ...

Wells Fargo analyst Yanan Zhu has maintained their bullish stance on ARCT stock, giving a Buy rating on January 15. Discover outperforming stocks and invest smarter with Top Smart Score Stocks ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...